Helius Medical Technologies, Inc. Compliant with Nasdaq’s Continued Listing Requirements
Helius Medical Technologies (Nasdaq: HSDT), a neurotech company specializing in therapeutic neuromodulation for balance and gait deficits, has achieved full compliance with Nasdaq's continued listing requirements. The company received formal confirmation on July 7, 2025 from the Nasdaq Hearings Panel regarding compliance with the equity requirement (Rule 5550(b)(1)).
This follows their earlier compliance confirmation with the minimum bid price requirement (Rule 5550(a)(2)) received on June 3, 2025. The company will be subject to a Mandatory Panel Monitor for one year following this notification.
Helius Medical Technologies (Nasdaq: HSDT), un'azienda neurotecnologica specializzata nella neuromodulazione terapeutica per deficit di equilibrio e deambulazione, ha raggiunto la piena conformità ai requisiti di quotazione continuativa del Nasdaq. La società ha ricevuto la conferma formale il 7 luglio 2025 dal Nasdaq Hearings Panel riguardo alla conformità al requisito patrimoniale (Regola 5550(b)(1)).
Ciò segue la precedente conferma di conformità al requisito del prezzo minimo di offerta (Regola 5550(a)(2)) ricevuta il 3 giugno 2025. La società sarà sottoposta a un Monitoraggio Obbligatorio del Panel per un anno dopo questa notifica.
Helius Medical Technologies (Nasdaq: HSDT), una empresa de neurotecnología especializada en neuromodulación terapéutica para déficits de equilibrio y marcha, ha logrado el cumplimiento total con los requisitos continuos de listado del Nasdaq. La compañía recibió la confirmación formal el 7 de julio de 2025 del Nasdaq Hearings Panel sobre el cumplimiento del requisito de capital (Regla 5550(b)(1)).
Esto sigue a la confirmación previa de cumplimiento con el requisito de precio mínimo de oferta (Regla 5550(a)(2)) recibida el 3 de junio de 2025. La empresa estará sujeta a un Monitor Obligatorio del Panel durante un año después de esta notificación.
Helius Medical Technologies (나스닥: HSDT)는 균형 및 보행 장애 치료용 신경조절에 특화된 신경기술 회사로, 나스닥 상장 유지 요건을 완전히 충족하였습니다. 회사는 2025년 7월 7일 나스닥 심의 패널로부터 자본 요건(규칙 5550(b)(1)) 준수에 대한 공식 확인을 받았습니다.
이는 2025년 6월 3일 최소 입찰 가격 요건(규칙 5550(a)(2)) 준수 확인을 받은 데 이은 것입니다. 회사는 이 통지 이후 1년간 의무 패널 모니터링 대상이 됩니다.
Helius Medical Technologies (Nasdaq : HSDT), une entreprise de neurotechnologie spécialisée dans la neuromodulation thérapeutique pour les déficits d'équilibre et de marche, a obtenu la pleine conformité aux exigences de maintien de la cotation du Nasdaq. La société a reçu la confirmation officielle le 7 juillet 2025 du Nasdaq Hearings Panel concernant la conformité à l'exigence de fonds propres (Règle 5550(b)(1)).
Cela fait suite à leur confirmation antérieure de conformité à l'exigence du prix minimum de l'offre (Règle 5550(a)(2)) reçue le 3 juin 2025. La société sera soumise à une surveillance obligatoire du Panel pendant un an après cette notification.
Helius Medical Technologies (Nasdaq: HSDT), ein Neurotechnologie-Unternehmen, das sich auf therapeutische Neuromodulation bei Gleichgewichts- und Gangstörungen spezialisiert hat, hat die vollständige Einhaltung der fortlaufenden Notierungsanforderungen der Nasdaq erreicht. Das Unternehmen erhielt am 7. Juli 2025 eine formelle Bestätigung vom Nasdaq Hearings Panel bezüglich der Einhaltung der Eigenkapitalanforderung (Regel 5550(b)(1)).
Dies folgt auf die frühere Bestätigung der Einhaltung der Mindestgebotspreisanforderung (Regel 5550(a)(2)) vom 3. Juni 2025. Das Unternehmen unterliegt nach dieser Benachrichtigung für ein Jahr einer verpflichtenden Panel-Überwachung.
- Company has regained full compliance with Nasdaq listing requirements
- Successfully met both equity and minimum bid price requirements
- Company will be under Mandatory Panel Monitor surveillance for one year
NEWTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that on July 7, 2025, Helius received formal notice from the Nasdaq Hearings Panel of the Nasdaq Stock Market LLC (the “Panel”) indicating that Helius has evidenced compliance with the equity requirement in Listing Rule 5550(b)(1) (the “Equity Rule”) for continued listing on the Nasdaq Capital Market.
As previously disclosed, on June 3, 2025, the Company received formal notification from Nasdaq confirming that the Company had regained compliance with the minimum bid price requirement, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company is currently in full compliance with NASDAQ continued listing requirements.
Pursuant to Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year from the date of this letter.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS® or Helius Medical Technologies, visit www.heliusmedical.com.
Cautionary Disclaimer Statement
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, but are not limited to, statements regarding the Company's ability to achieve and maintain compliance with the Nasdaq listing rules.
The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
Investor Relations Contact
Philip Trip Taylor
Gilmartin Group
investorrelations@heliusmedical.com
FAQ
Has Helius Medical Technologies (HSDT) regained Nasdaq compliance in 2025?
What Nasdaq requirements did HSDT meet to maintain listing?
What monitoring conditions apply to HSDT after regaining Nasdaq compliance?
What is Helius Medical Technologies' main business focus?
